{
    "clinical_study": {
        "@rank": "26880", 
        "arm_group": [
            {
                "arm_group_label": "experimental group", 
                "arm_group_type": "Experimental", 
                "description": "experimental group: Nedaplatin(\uff0880 mg/m2, i.v Day1\uff09in combination with Docetaxel\uff0875 mg/m2, i.v Day1\uff09for each cycle, 4 cycles in total."
            }, 
            {
                "arm_group_label": "comparative group", 
                "arm_group_type": "Active Comparator", 
                "description": "comparative group:Cisplatin (\uff0875 mg/m2, i.v  Day1 or 25 mg/m2 Day1-3\uff09in combination with Docetaxel\uff0875 mg/m2, i.v Day1\uff09for each cycle, 4 cycles in total"
            }
        ], 
        "brief_summary": {
            "textblock": "The treatment of squamous cell carcinoma of lung has not improved suffuciently. Nedaplatin\n      is a second-generation platinum compound that is more active against squamous cell carcinoma\n      of the lung with a response rate of 60%, issued by the finished Phase II trial in Japan."
        }, 
        "brief_title": "Nedaplatin (Jiebaishu\u00ae) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. primary lung squamous carcinoma confirmed by cytology and histology, excluding sputum\n             examination.\n\n          2. IIIB-no radiotherapy indication /IV phased by ASLC 2009 TNM criteria.\n\n          3. at least one measurable tumor based on RECIST ( longest diameter: \u226520 mm by CT scan\n             or 10 mm by spiral CT )\n\n          4. male or female, age\u226518 or \u226475 years old\n\n          5. ECOG PS: 0 or 1\n\n          6. estimated time of survival: \u226512 weeks\n\n          7. suitable hematologic function: ANC\u22652\u00d7109/L,  PLC\u2265100\u00d7109/L and Hb\u22659 g/dL\n\n          8. suitable liver function: Total bilirubin\u2264normal ULN, AST and ALT\u22642.5\u00d7normal ULN,\n             ALP\u22645\u00d7normal ULN.\n\n          9. suitable renal function: Cr\u2264normal ULN,or Ccr\u226560 ml/min\n\n         10. no history of chemotherapy\n\n         11. at the enrollment, the past operation has been over 4 weeks and the subject\n             recovered.\n\n         12. for the female subject with the intact uterus, if amenorrhea is less than 24 months,\n             pregnancy test must be negative within 28 days of enrollment. If pregnancy test has\n             been past 7 days at the time of initial chemotherapy, urine pregnancy test must be\n             done.\n\n         13. the authorized ICF must be signed\n\n        Exclusion Criteria:\n\n          1. having the other cancer in the recent five years, cured skin basal cell carcinoma and\n             cervical  carcinoma excluded.\n\n          2. having the evidence of CNS metastasis, no matter if treated; if being suspicious of\n             CNS metastasis, CNS MRI or enhanced CT scan must be done within 28 days of\n             enrollment.\n\n          3. AST and /or ALT\uff1e2.5\u00d7normal ULN, and ALP\uff1e5\u00d7normal ULN.\n\n          4. radiotherapy in the past (excluding palliative radiotherapy for pain relief and the\n             measurable tumor outside the radio field)\n\n          5. chemotherapy in the past (excluding bisphosphonates )\n\n          6. having the other uncontrolled diseases.\n\n          7. the female in pregnancy or feeding.\n\n          8. the subjects with the productivity capacity, but refusal to use the effective\n             contraception measure.\n\n          9. participating in other clinical trial and at the time of treatment period.\n\n         10. allergy to the tested drugs\n\n         11. having the other uncontrolled diseases\n\n         12. BMT had been done."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "290", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088515", 
            "org_study_id": "5501068"
        }, 
        "intervention": [
            {
                "arm_group_label": "experimental group", 
                "intervention_name": "Nedaplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "comparative group", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "experimental group", 
                    "comparative group"
                ], 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Nedaplatin", 
                "Docetaxel", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nedaplatin", 
            "lung squamous cell carcinoma"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "shun_lu@hotmail.com", 
                "last_name": "Shun Lu, MD", 
                "phone": "008613601813062"
            }, 
            "contact_backup": {
                "email": "chenzhiwei@gmail.com", 
                "last_name": "Zhiwei Chen, MD", 
                "phone": "008613916251926"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200000"
                }, 
                "name": "Shanghai Chest hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Shun Lu, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Zhiwei Chen, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Nedaplatin (Jiebaishu\u00ae) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study", 
        "other_outcome": {
            "description": "Adverse Events will be recorded and monitored till to normal or basal level achieved.", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "10 months"
        }, 
        "overall_contact": {
            "email": "Shun_lu@hotmail.com", 
            "last_name": "Shun Lu, MD", 
            "phone": "008613601813062"
        }, 
        "overall_contact_backup": {
            "email": "chenzhiwei@gmail.com", 
            "last_name": "Zhiwei Chen, MD", 
            "phone": "008613916251926"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "after being enrolled, the subjects will be subject to 4 cycles chemotherapy (each cycle: 21 days). if complete response/partial response/stable desease is confirmed, the subjects will be followed up till to the sixth months.", 
            "measure": "progress free survival", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the effectiveness will be evaluated after 2 cycles of chemotherapy is finished. 4 cycles of chemotherapy is needed for each subject.", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}